Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.200
Abstract: 200 Background: SM-88 (tyrosine derivative [Td], mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg Effect in combination with oxidative stress to cause tumor cell death.… read more here.
Keywords: phase trial; cancer; first stage; trial ... See more keywords